Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 1/2019

01-01-2019 | Alzheimer's Disease | Sleep (M Thorpy and M Billiard, Section Editors)

CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD

Authors: Claudio Liguori, Federico Paolini Paoletti, Fabio Placidi, Roberta Ruffini, Giulia Maria Sancesario, Paolo Eusebi, Nicola Biagio Mercuri, Lucilla Parnetti

Published in: Current Neurology and Neuroscience Reports | Issue 1/2019

Login to get access

Abstract

Purpose of Review

Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarce data are present in literature about the predictive role of cerebrospinal fluid (CSF) biomarkers. In this review, we focus on CSF biomarkers in patients with both iRBD and RBD associated with synucleinopathies to explore their potential predictive power.

Recent Findings

Recent studies revealed that CSF α-synuclein levels are higher in Parkinson’s disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD. In the Parkinson Progression Marker Initiative (PPMI) cohort, early PD patients with RBD show lower CSF Aβ42 levels, which predict faster cognitive decline. CSF prion protein and inflammatory biomarkers have been also investigated in RBD and synucleinopathies with controversial results.

Summary

A variety of CSF biomarkers are promising candidate for predicting iRBD conversion into synucleinopathies. Further studies are needed in iRBD patients followed for several years in order to observe the phenoconversion in synucleinopathies and to elucidate the possible role of CSF biomarkers as predictive biomarkers of conversion.
Literature
1.
Barone DA, Henchcliffe C. Rapid eye movement sleep behavior disorders and link to alpha-synucleinopathies. Clin Neurophysiol. 2018;129:1551–64.CrossRef
2.
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.CrossRef
3.
Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–8.CrossRef
4.
Schenck C, Bundlie S, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human rem sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.CrossRef
5.
Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord. 2007 Dec;22(16):2386–93.CrossRef
6.
American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd edition Darien. 2014.
7.
Ohayon MM, Caulet M, Priest RG. Violent behavior during sleep. J Clin Psychiatry. 1997;58(8):369–76.CrossRef
8.
Peever J, Luppi PH, Montplaisir J. Breakdown in REM sleep circuitry underlies REM sleep behavior disorder. Trends Neurosci. 2014;37(5):279–88.CrossRef
9.
Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.CrossRef
10.
Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.CrossRef
11.
Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75(6):494–9.CrossRef
12.
Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12:443–53.CrossRef
13.
De Cock VC. Restoration of normal motor control in Parkinson’s disease during REM sleep. Brain. 2007;130:450–6.CrossRef
14.
Postuma RB. REM sleep behavior disorders in Parkinson’s disease is associated with specific motor features. J Neurol Neurosurg Psychiatry. 2008;79:1117–21.CrossRef
15.
Palma JA, Fernandez-Cordon C, Coon EA, Low PA, Miglis MG, Jaradeh S, et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res Off J Clin Auton Res Soc. 2015;25:69–75.CrossRef
16.
Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875–82.CrossRef
17.
Ferini-Strambi L. Does idiopathic REM sleep behavior disorder (iRBD) really exist? What are the potential markers of neurodegeneration in iRBD? Sleep Med. 2011;12(Suppl 2):S43–9.CrossRef
18.
•• Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104–13 This paper documented that the use of simply assessed markers can identify patients with RBD to be included in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies. CrossRef
19.
Rocchi C, Placidi F, Liguori C, Del Bianco C, Lauretti B, Diomedi M, et al. Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. Sleep Med. 2018;52:163–7.CrossRef
20.
•• Li Y, Kang W, Yang Q, Zhang L, Zhang L, Dong F, et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology. 2017;88:1493–500 This research article suggested the predictive value of autonomic dysfunction and DAT uptake in identifying patients with iRBD at a high risk of progressing into neurodegenerative synucleinopathy diseases. CrossRef
21.
•• Iranzo A, Santamaria J, Valldeoriola F, Serradell M, Salamero M, Gaig C, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2017;82:419–28 This paper quantified the decreased FP-CIT putamen uptake as greater than 25% able to predict the conversion to synucleinopathy after 3 years' follow-up in idiopathic RBD patients. CrossRef
22.
Rodrigues Brazete J, Gagnon JF, Postuma RB, Bertrand JA, Petit D, Montplaisir J. Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. Neurobiol Aging. 2016;37:74–81.CrossRef
23.
•• Rolinski M, Griffanti L, Piccini P, Roussakis AA, Szewczyk-Krolikowski K, Menke RA, et al. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain. 2016;139:2224–34 Here Authors proved the very early dysfunction of basal ganglia connectivity in RBD, which was comparable to that of PD, despite obvious differences on dopamine transported single photon emission computerized tomography. CrossRef
24.
Frosini D, Cosottini M, Donatelli G, Costagli M, Biagi L, Pacchetti C, et al. Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism Relat Disord. 2017;43:105–9.CrossRef
25.
Marques O, Outeiro TF. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012;3(7):e350.CrossRef
26.
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson’s disease diagnosis and progression. Ann Neuol. 2011;69:570–80.CrossRef
27.
Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, de Carlo C, Qureshi MM, et al. Cerebrospinal fluid tau/αsynuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord. 2011;26:1428–35.CrossRef
28.
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230–40.CrossRef
29.
Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease. Mov Disord. 2014;29(8):1019–27.CrossRef
30.
Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF alphasynuclein species, tau, and Aβ42 in Parkinson’s disease. Front Aging Neurosci Internet. 2014;6(53).
31.
Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SAS, Kasai T, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson’s disease. Neurology. 2010;75:1766–70.CrossRef
32.
Wang Y, Shi M, Chung KA, et al. Phosphorylated synuclein in Parkinson’s disease. Sci Transl Med. 2012;4(121):121ra20–121ra20.
33.
Foulds PG, Yojota O, Thurston A, Davidson Y, Ahmed Z, Holton J, et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson’s disease and dementia with lewy bodies. Neurobiol Dis. 2012;45:188–95.CrossRef
34.
Aasly JO, Johansen KK, Brønstad G, et al. Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci. 2014;6:248.CrossRef
35.
Kang J-H, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluidβ-amyloid1-42,T-tau,P-tau181,andα-synucleinlevelswithclinical features of drug-naive patients with early Parkinson disease. JAMA Neurol Internet 2013;70:1277–1287.
36.
Jellinger KA. Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis. 2008;5(3–4):118–21.CrossRef
37.
Compta Y, Martí MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord. 2009;24(15):2203–10.CrossRef
38.
Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Aβ 42 and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25(15):2682–5.CrossRef
39.
Leverenz JB, Stennis Watson G, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(1):61–4.CrossRef
40.
• Compta Y, Valente T, Saura J, Segura B, Iranzo Á, Serradell M, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J Neurol. 2015;262(2):294–306 The Authors documented that CSF total-α-synuclein levels correlate with CSF tau and Aβ 42 levels, possibly suggesting that tau pathology may influence the presence of high (instead of low) CSF total-α-synuclein levels in the setting of PD-related dementia. CrossRef
41.
Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun Internet. 2006;345:967–72.CrossRef
42.
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7.CrossRef
43.
Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jørgensen HL, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord. 2012 Jan;18(1):69–72.CrossRef
44.
• Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Swedish BioFINDER study. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930–7 Authors firstly identified a blood biomarker (NfL) which can be used to distinguish PD from atypical parkinsonisms. CrossRef
45.
• Hu Y, Yu SY, Zuo LJ, Cao CJ, Wang F, Chen ZJ, et al. Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation. Neurology. 2015;84(9):888–94 Here, it was documented that elevated α-synuclein levels in CSF and serum may be correlated with RBD in PD patients through central and peripheral nervous systems inflammatory mechanisms. CrossRef
46.
Dolatshahi M, Pourmirbabaei S, Kamalian A, Ashraf-Ganjouei A, Yaseri M, Aarabi MH. Longitudinal alterations of alpha-synuclein, amyloid Beta, total, and phosphorylated tau in cerebrospinal fluid and correlations between their changes in Parkinson’s disease. Front Neurol. 2018;9:560.CrossRef
47.
• Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10):e894–905 Pagano and co-Authors proved that the presence of RBD in PD patients is associated with faster motor progression when greater synuclein and dopaminergic pathologies are present, and with higher risk of cognitive decline when greater synuclein and amyloid pathologies are present. CrossRef
48.
• Ba M, Yu G, Kong M, Liang H, Yu L. CSF Aβ1–42 level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder. Transl Neurodegener. 2018;7:22 This paper suggested that the addition of CSF Aβ 42 assessment to RBD increases the likelihood of identifying early PD patients at high risk for cognitive decline. CrossRef
49.
Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson’s disease features. Mov Disord. 2018;33(2):282–8.CrossRef
50.
Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders. Sci Rep. 2018;8(1):13276.CrossRef
51.
Zhang WJ, Shang XL, Peng J, Zhou MH, Sun WJ. Expression of prion protein in the cerebrospinal fluid of patients with Parkinson’s disease complicated with rapid eye movement sleep behavior disorder. Genet Mol Res. 2017;23:16 (1).
52.
•• Stokholm MG, Iranzo A, Østergaard K, Serradell M, Otto M, Svendsen KB, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16(10):789–96 This original research documented that increased microglial activation (detected by PET scans) in the substantia nigra along with reduced dopaminergic function in the putamen is present in patients affected by idiopathic RBD. CrossRef
Metadata
Title
CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD
Authors
Claudio Liguori
Federico Paolini Paoletti
Fabio Placidi
Roberta Ruffini
Giulia Maria Sancesario
Paolo Eusebi
Nicola Biagio Mercuri
Lucilla Parnetti
Publication date
01-01-2019
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 1/2019
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-019-0918-y

Other articles of this Issue 1/2019

Current Neurology and Neuroscience Reports 1/2019 Go to the issue

Neurorehabilitation and Recovery (J Krakauer and T Kitago, Section Editors)

Promoting Brain Repair and Regeneration After Stroke: a Plea for Cell-Based Therapies

Dementia (K Marder, Section Editor)

Defining Cognitive Reserve and Implications for Cognitive Aging

Neurorehabilitation and Recovery (J Krakauer and T Kitago, Section Editors)

Research in the Acute Rehabilitation Setting: a Bridge Too Far?

Pediatric Neurology (W Kaufmann, Section Editor)

Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy